new purine analogues, fludarabine and cladribine. Furthermore, positive selection of CD34 + cells may significantly reduce contamination of the autologous graft with B-CLL Successful stem cell mobilization and collection is possible in B-CLL after a favorable response to preceding cells. The data from 30 patients who received an autologous stem cell transplant to treat B-CLL, nine of which were chemotherapy, and also after treatment with the new nucleoside analogues fludarabine and cladribine. A poor with peripheral blood stem cells, have been reported to the EBMT/IBMT registries.
Patient characteristics are shown in Table 1 . All eight The clinical course of B-CLL is variable; in some patients patients had progressive disease, and five had stage C dis-CLL has an indolent course over several years, whereas in ease reflecting a heavy tumor burden. Prior to the first stem others it progresses rapidly in only a few years. The median cell mobilization, six patients were treated with fludarabine, survival of the patients who require treatment for their disone patient with fludarabine and cladribine, and one with ease is 4-5 years. Although the incidence of B-CLL peaks CHOP. Five of the patients were previously treated with among older persons, approximately one third of patients chlorambucil or COP, and two (patients 7 and 8) had are less than 60 years.
1,2 Thus, attempts to improve progbecome refractory to these regimens. In three patients nosis by using more intensive therapy are justified in treated with fludarabine, a second attempt of mobilization younger patients with B-CLL.
was performed after additional treatment with cladribine. A relatively small number of highly selected patients
The response criteria followed the ones presented by the with CLL who have undergone allogeneic progenitor cell National Cancer Institute-sponsored Working Group. 5, 6 transplantation have been reported to the European Blood The mobilization regimen consisted of cyclophosphamand Marrow Transplant (EBMT) and International Bone ide (CY) 4 g/m 2 followed by rhG-CSF at a dose of Marrow Transplant (IBMT) registries. In a recent analysis 5 g/kg/day s.c. as of the first day after CY to the end of of response rates in 70 patients receiving allogeneic bone harvesting. The optimal timing of the leukaphereses (LPs) marrow transplanted from HLA-identical sibling donors, was guided by the blood CD34 + cell count. LPs (Fenwal the post-transplant CR rate was 76%, and 42% of the CS-3000 Plus; Baxter, Fenwal Laboratories, Deerfield, IL, patients were alive at a median follow-up of 12 months. 3 USA) were started when the blood CD34 + cell count rose Nearly half the patients (42%) had progressive disease prior to around 20 × 10 6 /l, and were continued until the target to conditioning, which may partly explain the unacceptably CD34 + cell yield of 5 × 10 6 /kg was achieved. If this target high treatment-related mortality of approximately 50%. 4 yield could be harvested with two LPs on 2 successive Intensive therapy with autologous peripheral blood stem days, positive CD34 + selection (CellPro Ceprate SC; cell rescue is a new and promising treatment modality for Bothell, WA, USA) was performed (patients 1, 2 and 3). eradicating CLL in younger patients. Autologous stem cells
In patient 1, a previously collected and frozen graft was can be collected after effective reduction of tumor burden, thawed and used for CD34 + cell selection; in the others which currently can often be achieved with the use of the (patients 2 and 5), the selection procedure was performed with the fresh LP products. The CD34 + cell content of the blood specimen and the LP products were analyzed by flow CA, USA) after staining the cells with the phycoerythrin 
(PE)-conjugated anti-CD34-antibody (HPCA-2PE, Bectonobtained an excellent CR with no monoclonal cells after two additional cycles of cladribine. Three patients who Dickinson) and lysing the red blood cells with Ortho lysing solution (Ortho Diagnostics, Raritan, NJ, USA) according could not mobilize stem cells after receiving PR or SD with fludarabine were further treated with two additional courses to the Nordic standards. 7 Blood and bone marrow specimens as well as LP products were also analyzed by flow of cladribine. Two of these patients achieved CR, although they still have lymphocyte nodules and a monoclonal B cell cytometry for CD19
+ cells after staining with PEconjugated anti-CD19 (Becton-Dickinson) and FITC-conjupopulation in the bone marrow. One patient had only SD after the additional courses of cladribine. gated anti-CD5 (Becton-Dickinson). The clonal excess of immunoglobulin bearing cells was analyzed after staining
The data on blood CD34 + cell values, CD34 + yields, and graft quality after selection procedure are given in Table 3 . the mononuclear cells (isolated by gradient centrifugation) with FITC-conjugated anti-kappa and PC-conjugated antiIn patients 1-5 the target cell yield of 5 × 10 6 CD34 + cells/kg was achieved. All these patients had responded lambda (Simulset; Becton-Dickinson).
The conditioning regimen before ABCT consisted of well to the chemotherapy prior to mobilization (Table 1) . Patients 6-8 achieved only PR or SD on fludarabine treathigh-dose CY (120 mg/kg) for 2 consecutive days followed by fractionated total body irradiation of 12 Gy (10 Gy for ment, and a sufficient number of CD34 + cells could not be mobilized into blood in any of them. None of these patients the lungs) over 5 days. After the stem cell infusion, rhG-CSF at a dose of 5 g/kg/day s.c. was given as of the day could mobilize stem cells after an additional two courses of cladribine, even if two patients achieved hematological following the reinfusion until the blood neutrophil count exceeded 1.0 × 10 9 /l on 3 successive days. CR. Three patients had successful selection of CD34 + cells (patients 1, 2 and 5). In two patients LP products were not selected: in one patient (patient 3) the target stem cell yield required for mobilization could not be harvested by two Results consecutive LPs, and in another (patient 4) the LPs were inappropriately timed. Prior to mobilization, fludarabine was used to reduce the tumor burden in seven out of the eight patients; patient 4
The details of ABCT outcome of the five patients who underwent high-dose therapy and ABCT are shown in had achieved CR while on CHOP chemotherapy. According to the response criteria, three of the seven patients Table 4 . Two patients had CR with no monoclonal B cells before ABCT and three patients obtained a similar CR after treated with three to six courses of fludarabine achieved CR although there were signs of minimal residual disease: there ABCT. At a median follow-up of 10 months (range 2-16 months), four patients still have CR (Table 4) . The first was a monoclonal B cell population in the blood and bone marrow (Table 2) . Four patients treated with six courses patient relapsed at 16 months post-transplant and succumbed to her disease 18 months post-transplant. Two of fludarabine achieved only PR or SD. The bone marrow lymphocyte infiltration was 10% (nodular) in patient 7, patients have been readmitted to the hospital for infections at 1-14 months post-transplant while two other patients are 50% in patients 6 and 8, and 60-70% in patient 3 after six cycles of fludarabine. One of these patients (patient 3) doing well without any signs of infectious complications. Hematopoietic recovery: time to blood neutrophils 1.0 × 10 9 /l (Nph), platelets 20 × 10 9 /l and 50 × 10 9 /l, and blood hemoglobin100 g/l (Hb).
The recorded infections were herpes zoster, parvovirus B19 these high-quality CRs may translate into prolonged disease-free survival. Of some concern is the observation that infection with associated pure red cell aplasia, Salmonella sepsis and Pneumocystis carinii pneumonia in one patient, transient eradication of tumor cells may increase the risk of emerging resistant cell clones. 11 Our first CLL patient and Pneumocystis carinii pneumonia in the other. The latter patient also had treatment-related interstitial pneumonitis at who underwent ABCT relapsed 16 months post-transplant with rapidly progressing disease. Her disease, however, was 6 months post-transplant, and has been treated with corticosteroids.
already aggressive before the transplantation.
In the three patients in whom the CD34 + cell selection of the leukapheresis products was performed, a 2-to 3-log reduction of CD19/CD5 + cells was achieved by positive Discussion CD34 + cell selection of LP products. An open question remains, as in myeloma, whether some of the CD34 + proPromising results have been reported with high-dose therapy supported by autologous bone marrow transplantation genitor cells are derived from the malignant clone. 12 In addition to positive CD34 + cell selection, the grafts can be in incurable lymphoid malignancies other than CLL, such as multiple myeloma 8 and follicular lymphoma. 9 Less is purged by using monoclonal antibodies against B-CLL cells. 13 More data are required to establish whether these known about autologous bone marrow transplantation in CLL, but it seems that molecular complete responses are two purging methods differ from each other with regard to efficacy and feasibility in patients with B-CLL. Recovery also possible in CLL.
10, 11 We were interested to study if rapid and effective cytoreduction obtained with the new times of blood neutrophils and platelets seem comparable in patients receiving selected and unselected grafts nucleoside analogues fludarabine and cladribine allows collection of stem cells in CLL.
( Table 3 ). In one patient (patient 1) the selection procedure was, exceptionally, performed after thawing of a previously Our initial experience shows that CD34
+ progenitor cell grafts with a low number of residual B-CLL cells can be collected and frozen graft, which may explain a longer recovery. harvested after effective disease eradication of the CLL clone with chemotherapy, such as new nucleoside anaIn conclusion, it seems that previous therapy with nucleoside analogues obviously does not prevent successful logues. Seven of the patients had received nucleoside analogues; four patients had earlier received alkylating agents harvesting of peripheral blood stem cells. Instead, a good response to chemotherapy prior to mobilization may predict (chlorambucil), and four had fludarabine as their first-line treatment. Before mobilization, CR (as judged by the a good yield of stem cells. On the other hand, poor response to treatment with these regimens predicts a mobilization response criteria of the National Cancer Institute-sponsored Working Group 5,6 ) was obtained with fludarabine in three failure. Whether high-quality CRs, judged by immunophenotyping, obtained with high-dose therapy with autopatients, PR in two patients, and SD in two patients. Four patients received four to six cycles of treatment with fludalogous blood stem cell support translate into prolonged disease-free survival in B-CLL remains to be seen. rabine, one of them with additional cladribine, with a good response, and peripheral blood stem cells could be harvested successfully in all these patients. Three patients with only partial response to fludarabine failed to mobilize stem
